Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ORGANIZATION
ORGANIZATION
- FPMAJ to Set Up International Affairs Committee and Self-Medication Task Force
March 25, 2013
- JPMA Suspends Activities of Vice President Hasegawa for Six Months and Membership of Nihon Pharmaceutical
March 22, 2013
- JPMA Officially Decides on One-Year Postponement of Individual Payment Disclosures under Transparency Guidelines
March 22, 2013
- JPWA Vice President Ken Suzuki Expected to Lead JPWA After President Bessho’s Term Ends in May
March 22, 2013
- EFPIA Simulation: New Drug Market Up Mere 0.4 Trillion Yen by 2022 Even with Premium
March 19, 2013
- Transparency Guidelines: JPMA Proposes One-Year Hold on Disclosure of Individual Payments
March 18, 2013
- Japan Society of Generic Medicines Calls for 80% Generic Drug Share by Volume within 5 Years
March 8, 2013
- JPMA Issues Statement Calling for IP Protection, Expresses Concerns over Issuance of Compulsory Licenses
March 7, 2013
- Generic Market Share at 26.1% on Volume Basis in 3rd Quarter FY2012: JGA
March 6, 2013
- Relationships with Doctors Unchanged after Stricter Rules on Entertainment: Maker FTC Survey
February 27, 2013
- Yakukeiren’s Direct Joint Purchasing System for Generic Drugs to Go into Full Operation in FY2013
February 27, 2013
- TPP Hoped to Set Standard for Global IP Protection Rules: PhRMA Japan Rep. Wolf
February 25, 2013
- JPMA’s Nakatani Says Transparency Guidelines Will Go into Force in April as Planned
February 25, 2013
- JPMA’s New Code of Practice to Take Effect in April; Transparency in Relations with Wholesalers to Be One Focus
February 22, 2013
- Osaka-Based NPO to Take on Outsourcing of GMP Compliance Audit on Drug Substance Makers
February 21, 2013
- Pharmaceutical Trade Deficit “Not Directly Related to Global Competitiveness” of Domestic Industry: Mr Nagasawa of OPIR
February 20, 2013
- JMA to Host WMA Expert Conference on Revision of Helsinki Declaration in Tokyo on Feb. 28
February 20, 2013
- Biotech Association Asks MHLW to Include Drugs for Intractable Diseases and Orphan Drugs in Early Approval System
February 18, 2013
- JMA President Yokokura Opposes TPP Agreement, Expressing Concerns over Intervention in NHI Pricing
February 15, 2013
- PPTA President Airs Concern over Japanese Govt Intervention in Price Setting of Blood Products
February 13, 2013
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…